Aberdeen Group
AMLX icon

Aberdeen Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Aberdeen Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-738,657
Closed -$4.73M – 953
2025
Q2 		$4.73M Sell
738,657
-1,691,701
-70% -$8.23M 0.01% 710
2025
Q1 		$8.6M Buy
2,430,358
+707,553
+41% +$2.52M 0.02% 595
2024
Q4 		$6.51M Sell
1,722,805
-249,437
-13% -$1.17M 0.01% 600
2024
Q3 		$6.39M Buy
1,972,242
+1,853,995
+1,568% +$4.17M 0.01% 607
2024
Q2 		$225K Hold
118,247
– – ﹤0.01% 918
2024
Q1 		$336K Sell
118,247
-77,246
-40% -$1.01M ﹤0.01% 892
2023
Q4 		$2.88M Buy
+195,493
New +$3M 0.01% 746

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Aberdeen Group's AMLX Position: Q3 2025 in Review

Aberdeen Group sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2025, closing a stake of 738,657 shares — an estimated $4.73M sold.

Aberdeen Group first reported a position in AMLX in Q4 2023 and held it in 7 quarters. The position peaked at $8.6M in Q1 2025. 169 funds tracked by Wall St. Rank hold AMLX as of Q3 2025.

  • Aberdeen Group reported no remaining Amylyx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Aberdeen Group sold 738,657 Amylyx Pharmaceuticals shares in Q3 2025, an estimated $4.73M.
  • Aberdeen Group first reported a position in Amylyx Pharmaceuticals in Q4 2023 and held it in 7 quarters.
  • Aberdeen Group's Amylyx Pharmaceuticals position peaked at $8.6M in Q1 2025.
  • 169 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2025.

Based on Aberdeen Group's 13F filing for Q3 2025, filed 7 Nov 2025.